BIOAGE LABS, INC. Operating Lease, Expense
BIOAGE LABS, INC. (BIOA) reported Operating Lease, Expense of $200.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-05
- BIOAGE LABS, INC. operating lease, expense for the quarter ending 2026-06-30 was $200.00K, a 50.00% decline year-over-year.
- BIOAGE LABS, INC. operating lease, expense for the quarter ending 2026-03-31 was $200.00K, a 100.00% increase year-over-year.
- BIOAGE LABS, INC. operating lease, expense for the quarter ending 2025-12-31 was $200.00K, a 100.00% increase year-over-year.
- BIOAGE LABS, INC. operating lease, expense for the quarter ending 2025-09-30 was $200.00K, a 100.00% increase year-over-year.
- BIOAGE LABS, INC. operating lease, expense for fiscal 2025 was $800.00K, a 166.67% increase from fiscal 2024.
- BIOAGE LABS, INC. operating lease, expense for fiscal 2024 was $300.00K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 9 month as first filed | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $200.00K 10-Q · filed 2026-08-05 | $400.00K 10-Q · filed 2026-08-05 | $600.00K derived: sum of 3 quarters · filed 2026-08-05 | $800.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $200.00K 10-Q · filed 2026-05-08 | $400.00K derived: sum of 2 quarters · filed 2026-05-08 | $600.00K derived: sum of 3 quarters · filed 2026-05-08 | $1.00M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $400.00K derived: sum of 2 quarters · filed 2026-03-24 | $800.00K derived: sum of 3 quarters · filed 2026-08-05 | $800.00K 10-K · filed 2026-03-24 | |
| 2025-09-30 | $200.00K 10-Q · filed 2025-11-06 | $600.00K derived: sum of 2 quarters · filed 2026-08-05 | $600.00K 10-Q · filed 2025-11-06 | $800.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $400.00K 10-Q · filed 2026-08-05 | $600.00K 10-Q · filed 2026-08-05 | $600.00K derived: sum of 3 quarters · filed 2026-08-05 | $700.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $100.00K 10-Q · filed 2026-05-08 | $200.00K derived: sum of 2 quarters · filed 2026-05-08 | $300.00K derived: sum of 3 quarters · filed 2026-05-08 | $400.00K derived: sum of 4 quarters · filed 2026-05-08 | |
| 2024-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $200.00K derived: sum of 2 quarters · filed 2026-03-24 | $300.00K derived: sum of 3 quarters · filed 2026-03-24 | $300.00K 10-K · filed 2026-03-24 | |
| 2024-09-30 | $100.00K 10-Q · filed 2025-11-06 | $200.00K derived: sum of 2 quarters · filed 2025-11-06 | $200.00K 10-Q · filed 2025-11-06 | $3.00K 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $100.00K 10-Q · filed 2025-08-06 | $200.00K 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | $100.00K 10-Q · filed 2025-05-06 | ||||
| 2023-09-30 | $2.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |